SGM-101
Pancreatic Ductal Adenocarcinoma (for surgical guidance)
Key Facts
About SurgiMab
SurgiMab is a French biotech pioneer in near-infrared fluorescence-guided surgery and diagnostics. Its core platform conjugates tumor-targeting monoclonal antibodies with fluorescent dyes to illuminate cancerous tissue during procedures, enabling surgeons to achieve more complete resections. The company's lead asset, SGM-101, targets Carcinoembryonic Antigen (CEA) and is in Phase II trials for pancreatic cancer, with demonstrated utility in colorectal and lung cancers. SurgiMab's mission is to enhance cancer care through real-time visualization, aiming to reduce recurrence and improve patient outcomes.
View full company profileAbout SurgiMab
SurgiMab is a French biotech pioneer in near-infrared fluorescence-guided surgery and diagnostics. Its core platform conjugates tumor-targeting monoclonal antibodies with fluorescent dyes to illuminate cancerous tissue during procedures, enabling surgeons to achieve more complete resections. The company's lead asset, SGM-101, targets Carcinoembryonic Antigen (CEA) and is in Phase II trials for pancreatic cancer, with demonstrated utility in colorectal and lung cancers. SurgiMab's mission is to enhance cancer care through real-time visualization, aiming to reduce recurrence and improve patient outcomes.
View full company profileAbout SurgiMab
SurgiMab is a French biotech pioneer in near-infrared fluorescence-guided surgery and diagnostics. Its core platform conjugates tumor-targeting monoclonal antibodies with fluorescent dyes to illuminate cancerous tissue during procedures, enabling surgeons to achieve more complete resections. The company's lead asset, SGM-101, targets Carcinoembryonic Antigen (CEA) and is in Phase II trials for pancreatic cancer, with demonstrated utility in colorectal and lung cancers. SurgiMab's mission is to enhance cancer care through real-time visualization, aiming to reduce recurrence and improve patient outcomes.
View full company profile